Prolia is expensive primarily because it’s a biologic medication, not a traditional pill. Biologics are manufactured using living cells in a complex process that costs far more than producing standard drugs. A single dose of Prolia typically runs between $1,500 and $2,000 before insurance, and patients need two injections per year, putting the annual list price in the range of $3,000 to $4,000. Several factors stack on top of each other to keep that price high.
Biologics Cost More to Make
Traditional osteoporosis pills like alendronate (the generic version of Fosamax) are small-molecule drugs produced through straightforward chemical reactions. They’ve been available as generics for years and cost as little as $10 to $30 per month. Prolia is fundamentally different. It’s a monoclonal antibody, a large, engineered protein grown inside living cell cultures. Manufacturing biologics requires specialized facilities, strict temperature controls, and extensive quality testing at every stage. Each batch takes weeks to produce, and even minor contamination can ruin an entire run. Those production costs get passed along to patients.
The complexity also makes biologics harder to copy. Unlike a generic pill, which contains the same chemical formula as the original, a “biosimilar” can only approximate the original biologic. Creating one requires years of analytical testing and clinical trials to prove it works comparably. That barrier has kept competitors off the market for over a decade.
No Biosimilar Competition Until Recently
Amgen, the company that makes Prolia, has been the sole manufacturer of denosumab since the drug was approved in 2010. Without competition, there’s been no market pressure to lower the price. That’s finally starting to change. The FDA has approved multiple denosumab biosimilars in recent months, including products approved in September, October, and December of 2025, and another in March 2026. At least five different biosimilar versions now have FDA approval.
However, FDA approval doesn’t mean these products are on pharmacy shelves yet. Patent disputes, manufacturing ramp-up, and insurance formulary negotiations all create delays between approval and actual availability. When biosimilars do reach the market, they typically launch at a 15% to 35% discount compared to the original brand. That discount tends to grow as more competitors enter. For patients paying out of pocket, this could eventually mean meaningful savings, but the timeline remains uncertain.
It Requires a Medical Office Visit
Prolia isn’t a drug you pick up at the pharmacy and take at home. It’s a subcutaneous injection given by a healthcare provider every six months. That means every dose comes with an office visit or infusion center charge on top of the drug cost itself. The administration fee varies widely depending on the setting. A doctor’s office might charge $25 to $75, while a hospital outpatient facility could bill several hundred dollars for the same injection.
This setup also affects how insurance processes the claim. Rather than running through your prescription drug benefit, Prolia is often billed as a medical procedure, which can mean different deductibles, different coinsurance rates, and different out-of-pocket maximums than you’d expect from a typical prescription.
How Medicare Covers Prolia
For people on Medicare, Prolia is generally covered under Part B (medical insurance) rather than Part D (prescription drug coverage), because it’s administered by a healthcare provider. After meeting the Part B deductible, you typically pay 20% of the Medicare-approved amount. On a drug that costs over $1,500 per dose, that 20% coinsurance can still be several hundred dollars per injection.
There’s one important exception. Medicare Part B covers injectable osteoporosis drugs under a narrower set of conditions for home administration: you must be a woman with postmenopausal osteoporosis, qualify for Medicare home health services, have a fracture related to osteoporosis, and be unable to self-inject. If you meet all those criteria, Medicare covers the home health nurse visit at no cost to you. Most Prolia patients, though, receive their injections in a clinic and pay the standard 20% coinsurance.
One recent change worth knowing about: Medicare coinsurance for certain Part B drugs can be reduced if the drug’s price has risen faster than inflation. The specific drugs and savings amounts change quarterly, so it’s worth checking whether Prolia qualifies in the current period.
What You Actually Pay Depends on Your Insurance
The gap between Prolia’s list price and what you pay out of pocket varies enormously. With commercial insurance that covers specialty biologics, your cost might be a copay of $30 to $100 per injection. With a high-deductible plan, you could be responsible for the full price until you hit your deductible. Without insurance, you’re looking at the full list price plus administration fees.
Amgen offers a copay assistance card for commercially insured patients, which can reduce out-of-pocket costs significantly. The exact maximum annual benefit isn’t publicly listed on their site, but copay cards for specialty biologics commonly cap at $10,000 to $15,000 per year, which is more than enough to cover most patients’ share of two annual doses.
Financial Assistance for Uninsured Patients
If you don’t have insurance, the Amgen Safety Net Foundation may provide Prolia at no cost. Eligibility is based on income and residency. For 2026, the household income limits are $47,880 for a single person, $64,920 for two people, $81,960 for three, and $99,000 for four, with $17,040 added for each additional household member. You must have lived in the U.S. or its territories for at least six months and have no insurance coverage. Qualifying Medicare patients who face an affordability gap and don’t have access to other financial support programs may also be eligible.
Independent copay foundations, such as the Patient Access Network Foundation and the HealthWell Foundation, sometimes offer grants for osteoporosis medications as well. These funds open and close depending on available donations, so checking periodically is worthwhile if you’re denied on your first attempt.
Why Not Switch to a Cheaper Alternative?
This is where Prolia’s pricing becomes especially frustrating. Generic alendronate costs a fraction of the price and is the first-line treatment for most people with osteoporosis. But Prolia isn’t prescribed arbitrarily. It’s typically reserved for patients who can’t tolerate oral bisphosphonates (due to digestive side effects or esophageal problems), who have kidney issues that rule out other options, or whose bone density hasn’t responded adequately to cheaper treatments. For these patients, Prolia isn’t a luxury choice. It fills a gap that generics can’t.
Other branded alternatives carry their own high price tags. Injectable options like zoledronic acid (given once yearly by IV) tend to cost less than Prolia but still involve facility fees. Newer anabolic agents that build bone rather than just slowing its loss can cost $20,000 or more per year. In the current landscape, Prolia sits in an uncomfortable middle ground: too expensive for comfort, but often the most practical option for patients who need more than a generic pill.